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Abstract
Carbapenem-hydrolysing b-lactamases are the most powerful b-lactamases, being able to hydrolyse almost all b-lactams. They are
mostly of the KPC, VIM, IMP, NDM and OXA-48 types. Their current extensive spread worldwide in Enterobacteriaceae is an important
source of concern, as these carbapenemase producers are multidrug-resistant. Detection of infected patients and of carriers are the
two main approaches for prevention of their spread. Phenotypic and molecular-based techniques are able to identify these carbapenem-
ase producers, although with variable efﬁciencies. The detection of carriers still relies mostly on the use of screening culture media.
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Multidrug resistance is now emerging at an alarming rate
among a variety of bacterial species, causing both nosocomial
and community-acquired infections. One of the most impor-
tant emerging traits is resistance to extended-spectrum b-lac-
tams in Gram-negative bacilli. Increasing resistance to
carbapenems, which are most often the last line of therapy, is
now frequently being observed in many hospital-acquired and
several community-acquired Gram-negatives rods. Carbape-
nem-resistant Enterobacteriaceae have now been reported
worldwide. This may be related either to an association of
decreased outer membrane permeability with overexpression
of b-lactamases possessing very weak carbapenemase activity,
or to expression of carbapenemases [1–6]. Their carbapenem
resistance trait is not transferable, unlike most of the carbape-
nemase genes, and porin defect may have a signiﬁcant ﬁtness
cost. This explains why carbapenem-resistant isolates that do
not produce carbapenemases are considered to be much
less important from a public health perspective than
carbapenemase producers. The spread of carbapenemase pro-
ducers is by far the most important current clinical issue in
antibiotic resistance in Gram-negatives, and must be strictly
controlled.
The ﬁrst carbapenemase identiﬁed in Enterobacteriaceae
was the chromosomally encoded NmcA from an Enterob-
acter cloacae clinical isolate in 1993 [7]. Since then, carba-
penem-resistant Enterobacteriaceae have been reported
worldwide, mostly as a consequence of acquisition of carb-
apenemase genes. A large variety of carbapenemases have
been identiﬁed in Enterobacteriaceae, belonging to three
classes of b-lactamase, the Ambler class A, B and D b-lac-
tamases, which have been extensively described elsewhere
[6]. In addition, rare chromosomally encoded cephalospo-
rinases (Ambler class C/AmpC) produced by Enterobacteria-
ceae may possess slightly extended activity towards
carbapenems, but their clinical signiﬁcance remains debat-
able [6].
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True carbapenemases hydrolyse most b-lactams, includ-
ing the carbapenems (imipenem, ertapenem, meropenem,
and doripenem) [6]. The most clinically signiﬁcant Ambler
class A carbapenemases are of the KPC type [6,8,9]. They
hydrolyse all b-lactams, and their activity is inhibited by
boronic acid and, at least partially, by clavulanic acid and
tazobactam (Table 1). The class B b-lactamases are the
enzymes possessing the highest carbapenemase activity.
They are mostly of the IMP, VIM and NDM types in
Enterobacteriaceae [6,10,11]. These enzymes exhibit a broad
spectrum of hydrolytic activity, including all penicillins,
cephalosporins, and carbapenems, sparing only the mono-
bactam aztreonam (Table 1) [6,11]. Their activity is not
inhibited by commercially available b-lactamase inhibitors
(clavulanic acid, tazobactam, or sulbactam) [6,11]. The
mechanism of hydrolysis of class B enzymes is dependent
on the interaction of the b-lactam with zinc ion(s) in their
active site, explaining the inhibition of their activity by
EDTA, a chelator of divalent cations, or dipicolinic acid
[11–13]. The Ambler class D enzymes with carbapenemase
activity in Enterobacteriaceae are mostly OXA-48 and
OXA-181 [6]. They have a peculiar hydrolysis proﬁle,
sparing ceftazidime, hydrolysing cefotaxime at a very low
level, and being resistant to inhibition by clavulanic acid–
tazobactam (Table 1) [6]. Clinical isolates rarely show the
phenotype of resistance that is attributable to carbapenem-
ase expression alone, because they often have other
co-resident b-lactamases such as extended-spectrum b-lacta-
mases (ESBLs), leading to a broader composite resistance
proﬁle (Table 1) [6].
Most carbapenemase producers are Klebsiella pneumoniae
or Escherichia coli, and although they are being increasingly
identiﬁed worldwide, there are some clear endemic areas,
such as KPC producers in the USA, Greece, and Israel [9],
VIM producers in Greece [6,13], OXA-48 producers in
North Africa and Turkey [6], and NDM producers in the
Indian subcontinent and possibly the Balkans [9].
Accurate detection of carbapenemase-producing Entero-
bacteriaceae is required in two situations: detection in clinical
specimens; and detection of colonizing strains that have
grown on media used to screen for carriers.
Detection
Detection of carbapenemase producers in Enterobacteriaceae
is becoming a major issue, as carbapenemases are usually
associated with many other resistance determinants, giving
rise to multidrug resistance and even pandrug resistance.
The detection of carbapenemase producers in clinical
specimens is based ﬁrst on a careful analysis of susceptibility
testing results obtained with automated systems, liquid
media, and disk diffusion tests. Automated systems may not
reliably detect all types of carbapenemase producer, and dis-
crepancies may arise [14]. The CLSI (USA) breakpoints for
carbapenems have been lowered signiﬁcantly to permit bet-
ter detection of carbapenem-resistant isolates (Table 2)
[15,16]. Ertapenem seems to be a good candidate for detect-
ing most of the carbapenemase producers, as MICs of
ertapenem are usually higher than MICs of other carbapenems
(Table 3) [17]. However, detection of carbapenemase
producers based only on MIC values of ertapenem lacks
speciﬁcity. According to these CLSI and EUCAST guidelines,
breakpoints are all that are needed for making treatment
decisions. Special tests for carbapenemase detection are
TABLE 1. Resistance phenotypes
resulting from the expression of
the main carbapenemases repor-
ted in Enterobacteriaceae without
or with extended-spectrum b-lacta-
mases (ESBLs)
AMX AMC TZP CTX CAZ IMP ETP MER ATM
KPC R S/I R R R S/I/R I/R S/I/R R
KPC + ESBL R I/R R R R I/R I/R I/R R
IMP/VIM/NDM R R I/R R I/R S/I/R I/R S/I/R S
IMP/VIM/NDM + ESBL R R I/R R R I/R R S/I/R R
OXA-48/OXA-181 R R S/I/R S/I S S/I S/I S/I S
OXA-48/OXA-181 + ESBL R R I/R R R I/R I/R I/R R
AMX, amoxycillin; AMC, amoxycillin–clavulanic acid; TZP, piperacillin–tazobactam; CTX, cefotaxime; CAZ, ceftazi-
dime; IMP, imipenem; ETP, ertapenem; MER, meropenem; ATM, aztreonam.
TABLE 2. Breakpoint values for carbapenems according to
the US (CLSI) and European (EUCAST) guidelines, as upda-
ted June 2010 (MIC values, mg/L)
CLSI EUCAST
S (£) R (‡) S (£) R (>)
Imipenem 1 4 2 8
Meropenem 1 4 2 8
Ertapenem 0.5 2 0.5 1
Doripenem 1 4 2 8
TABLE 3. Range of MICs of carbapenems for clinical Entero-
bacteriaceae expressing the main carbapenemases
MIC (mg/L)
Imipenem Meropenem Ertapenem
KPC 0.5 to >32 0.5 to >32 0.5 to >32
IMP/VIM/NDM 0.5 to >32 0.5 to >64 0.38 to >32
OXA-48/OXA-181 0.25 to 64 0.38 to 64 0.38 to >32
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recommended only for epidemiology and infection control
issues.
However, intermediate susceptibility and even susceptibil-
ity to carbapenems have been observed for producers of all
types of carbapenemase (Table 3). This is particularly true
for OXA-48/OXA-181 producers that do not co-produce an
ESBL [6,18,19]. Therefore, we believe that a search for carb-
apenemase production should be performed in any entero-
bacterial isolates with any slight decrease in susceptibility to
carbapenems. This belief is supported in part by the current
paucity of clinical experience in treating infections caused by
carbapenemase producers, the high inoculum of carbapenem-
ase producers in the site of the infection in vivo (e.g. pneu-
monia), and the possibility of selecting in vivo mutants with
increased levels of resistance to carbapenems and possessing
additional mechanisms that contribute to carbapenem resis-
tance. In addition, using an experimental model of peritonitis
in mice infected with an OXA-48 producer, we showed
recently that imipenem and ertapenem failed to cure infected
mice despite their low MIC values [20]. There is no consen-
sus on the cut-off value of MICs of carbapenems that should
be applied for research into carbapenemase activity. On the
basis of the literature and our own experience, we propose
that investigations of carbapenemase activity should be per-
formed on enterobacterial isolates with MIC values of
‡0.5 mg/L for ertapenem or ‡1 mg/L for imipenem and me-
ropenem. We are aware that these values may lead to the
inclusion of several enterobacterial species for which the nat-
ural distribution of MICs of imipenem is around 1 mg/L (e.g.
Proteus species). However, this seems to be the best com-
promise in order to maximize detection sensitivity. The use
of meropenem instead may be proposed, as there is a
broader corridor between the wild-type and clinical break-
points.
A series of non-molecular-based tests have been proposed
for detection of carbapenemase activity. None of the currently
available tests has 100% speciﬁcity or 100% sensitivity. The
modiﬁed Hodge test (MHT) based on in vivo production of a
carbapenemase by a carbapenemase-producing strain has been
suggested, in particularly in the USA [21–24]. This technique
is, however, time-consuming, as it requires at least 24–48 h. It
often lacks speciﬁcity (e.g. false-positive results for high-level
AmpC producers or CTX-M-type ESBL producers, Enterobact-
er species) and sensitivity (e.g. weak detection of NDM pro-
ducers), but works well for the detection of KPC and OXA-48
producers. The sensitivity of the MHT in detecting NDM pro-
ducers is signiﬁcantly improved if zinc is included in the culture
medium (Biceˆtre MHT) [25]. This test can be used as the ﬁrst
step in detecting the carbapenemase activity of candidate iso-
lates. In addition, it is also useful for checking carbapenemase
activity as part of the infection control process for outbreaks
caused by carbapenemase producers.
Concomitantly with performance of the MHT, inhibition
studies can be performed in liquid or solid culture media
with molecules that inhibit the activity of several types of
carbapenemase and/or other types of b-lactamase. Inhibition
by EDTA or dipicolinic acid may be used for the detection
of MBL activity [12,13,22]. The Etest MBL strip (AB bio-
Me´rieux, Solna, Sweden) is one of the methods advocated
for this purpose [6,11]. This latter method, using imipenem
and imipenem/EDTA, is efﬁcient in detecting MBL producers
exhibiting high-level resistance but may fail to detect MBL
producers exhibiting low-level resistance to imipenem. Novel
Etest strips containing other concentrations of inhibitors or
other carbapenem molecules (meropenem) will be available
soon, and may facilitate this detection. Boronic acid-based
inhibition testing has been reported to be speciﬁc for KPC
detection in K. pneumoniae when performed with imipenem
or meropenem [26]. Although these phenotypic tests are
adequate for the detection of carbapenemases in AmpC-neg-
ative enterobacterial species such as K. pneumoniae, they
have some limitations for the identiﬁcation of carbapenemase
producers among AmpC-positive species such as Enterobacter
species. Inhibition of cephalosporinase activity by plating
these strains on cloxacillin-containing plates or using cloxacil-
lin-containing tablets may help to differentiate those strains
that will recover a susceptibility to carbapenems (most hy-
perproducers of cephalosporinases) from those that exhibit
low-level carbapenem resistance owing to the production of
a carbapenemase [12]. Boronic acid also inhibits the activity
of chromosome-encoded or plasmid-encoded AmpC-like
cephalosporinases. Therefore, it is useful to compare boronic
acid inhibition with that obtained in presence of cloxacillin
(cloxacillin-containing plates or disk). To this end, an algo-
rithm has been proposed for the accurate detection of carb-
apenemase producers in enterobacteria, including the use of
cloxacillin for the discrimination of AmpC hyperproducers
[12], and there are also commercially available methodo-
logies based on the same concept (Rosco Diagnostica,
Copenhagen, Denmark).
None of these inhibition tests is suitable for detecting
OXA-48/OXA-181 producers, because the activity of these
enzymes is not inhibited by clavulanic acid, tazobactam, sul-
bactam, or any zinc chelators. High-level resistance to both
temocillin (MICs of >64 mg/L) and piperacillin–tazobactam in
Enterobacteriaceae showing reduced susceptibility or resis-
tance to at least one carbapenem may be used as a ﬁrst step
towards identifying possible OXA-48 producers [27].
Carbapenemase detection by spectrophotometric assay is
the most accurate approach advocated for the detection of
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carbapenemases. This technique, which is detailed elsewhere
(S. Bernabeu, L. Poirel, P. Nordmann, unpublished data), is
based on the measurement of imipenem hydrolysis at a
wavelength of 297 nm by a carbapenemase-containing extract
obtained after 18 h of culture in broth. It can accurately
differentiate between carbapenemase producers and carbape-
nem-resistant bacteria with non-carbapenemase-mediated
mechanisms of resistance (i.e. outer membrane permeability
defect, or overproduction of cephalosporinases and/or
ESBLs). In addition, it is cheap in comparison with any other
available molecular technique. However, it does not discrimi-
nate between the different types of carbapenemase, and
requires a preliminary step of at least 12 h of bacterial cul-
ture and speciﬁc training. Despite this, it has excellent sensi-
tivity and speciﬁcity for detecting carbapenemase activity in
Enterobacteriaceae. It should be implemented in any national
reference laboratory. Recently, the use of mass spectrometry
to detect carbapenemase activity has been proposed,
based on analysis of the degradation spectrum of a
carbapenem molecule [28,29]. Although this technique must
be further evaluated, matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry equipment is
increasingly being used in both reference and diagnostic
bacteriology laboratories.
Molecular techniques remain the reference standard for
the identiﬁcation and differentiation of carbapenemases. Most
are based on PCR, and may be followed by sequencing if
needed for precise identiﬁcation of a carbapenemase, rather
than just its group (e.g. VIM-type, KPC-type, NDM-type, and
OXA-48-type). They are either single PCR techniques or
multiplex PCR techniques [30–32]. The PCR technique per-
formed on colonies can give results within 4–6 h (or less
when real-time PCR technology is used), with excellent sen-
sitivity and speciﬁcity. Similarly, other molecular techniques
are useful for this purpose [33]. Sequencing of PCR products
is interesting mostly for epidemiological purposes. The main
disadvantages of the molecular-based technologies for detec-
tion of carbapenemase genes are their cost, the requirement
for trained technicians, and the inability to detect novel carb-
apenemase genes.
Screening of Carriage
The prevention of spread of carbapenemase producers relies
on early and accurate detection of carriers in hospital units
or on admission/discharge either to the hospital or to a spe-
ciﬁc unit. But who must be screened? Several countries have
introduced policies or have recommendations and guidance
on which patients should be screened, although the details
differ considerably between countries, as does the degree to
which the screening is mandated [34,35]. Screening should
include at least ‘at-risk’ patients, such as those in intensive-
care units, and transplantation and immunocompromised
patients. If a patient is conﬁrmed as being infected or colo-
nized by a carbapenemase producer, the screening pro-
gramme should be extended to neighbouring patients on the
hospital ward. Screening shall be done at least to patients
transferred from a foreign hospital on addition to any hospi-
tal unit.
As the reservoir of Enterobacteriaceae is mostly the intesti-
nal ﬂora, stools and rectal swabs are the most suitable speci-
mens for performing this screening process. These
specimens may be plated on screening medium (see below),
either directly or after an 18-h enrichment in broth contain-
ing imipenem 0.5–1 mg/L or ertapenem 0.5 mg/L [36,37].
The beneﬁts of this enrichment step have not been exten-
sively evaluated, although it has been shown to improve the
detection of KPC producers [36]. It may be useful when
managing an outbreak or searching for additional carriers
when a carbapenemase producer is found in stools. The main
disadvantage of this culture step is that it delays results by
18–24 h. Thus, the time needed to conﬁrm or refute carba-
penemase activity may be up to 72 h after the sample is
taken from the patient.
Stools or rectal swabs (with or without enrichment in the
presence of a carbapenem) should be plated on selective
media. The problem is that the level of resistance to carba-
penems displayed by carbapenemase producers varies signiﬁ-
cantly, making their detection difﬁcult unless they show high-
level carbapenem resistance [38,39].
Several studies have reported using media containing im-
ipenem at 1–2 mg/L, which may be too high a concentra-
tion for efﬁcient detection of carbapenemase producers
with low-level resistance (e.g. the OXA-48/OXA-181 pro-
ducers). One would therefore expect the speciﬁcity to be
quite good but the sensitivity to be poor. A culture med-
ium initially designed to screen for ESBL producers that
contains cefpodoxime (ChromID ESBL; bioMe´rieux, La
Balme-les-Grottes, France) and a carbapenem-containing
medium (CHROMagar KPC; CHROMagar, Paris, France)
have been evaluated for screening carbapenemase produc-
ers [38,39]. Both media contain chromogenic molecules
that may contribute to enterobacterial species recognition.
The ChromID ESBL medium has excellent sensitivity, its
main disadvantage being the lack of detection of OXA-48-
like producers that are susceptible to cefpodoxime, i.e. in
the absence of co-production of an ESBL. In addition, it
lacks speciﬁcity for carbapenemase producers, as it was
formulated to support the growth of ESBL producers [40].
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This is an important consideration, because of the wide-
spread carriage of ESBL producers worldwide, and necessi-
tates additional testing of colonies for carbapenem
resistance. The CHROMagar KPC medium detects carba-
penemase producers only if they exhibit higher-level resis-
tance to carbapenems [41,42]. Its main disadvantage is
therefore its lack of sensitivity, as it does not detect carb-
apenemase producers with low levels of carbapenem resis-
tance. Although it has not been extensively evaluated, the
use of two parallel plates for detection of a carbapenem-
ase producer may be possible with an ESBL screening
plate and a Drigalski plate on which an ertapenem disk or
an Etest strip is placed [43,44]. A novel and patented
medium (SUPERCARBA medium) containing cloxacillin, zinc
and a carbapenem molecule that has improved sensitivity
and speciﬁcity for detecting all types of carbapenemase
producer (including OXA-48 producers) has been recently
developed [45].
None of these culture-based approaches will identify the
type of carbapenemase. The screening process requires
patients to be kept in strict isolation prior to results being
obtained (at least 48 h). Actually, after this screening step,
carbapenemase producers must then be identiﬁed with to the
techniques described above (antibiotic susceptibility testing
and molecular techniques). Recently, PCR-based techniques
performed directly on stool specimens have been proposed
for the rapid detection of KPC and NDM-1 producers [46,47].
Such methods will speed up detection, and may be especially
useful in outbreak investigations. However, the cost-effective-
ness of such approaches and the predictive value of a positive
test result in low-prevalence settings needs to be considered;
as yet, little is known about the occurrence of enterobacterial
carbapenemase genes in the normal, and perhaps non-cultur-
able, bowel ﬂora, so there is a potential for molecular tests to
have lower speciﬁcity than might be intuitively predicted. It is
imperative to point out that the screening process on admis-
sion still requires the patients to be kept in strict isolation
prior to results being obtained (at least for 48 h).
Conclusion
The worldwide spread of Enterobacteriaceae expressing
carbapenemases represents a major signiﬁcant threat of
public health concern. Signiﬁcant efforts are needed
to ensure prompt and accurate detection, and the
implementation of effective infection control strategies.
Screening procedures should be implemented worldwide
for ‘at-risk’ patients. These procedures represent an essen-
tial component of the efforts needed to prevent the
further development of infections caused by multidrug-
resistant or even pandrug-resistant bacteria in hospitals.
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